Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4.75% is 25% above its 5-year average of -6.36%, near the high end of its 5-year range (-805.67%–12.47%).
96.16% above its 12-month average of -123.73%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-05-31): 5.27%.
EBITDA MARGIN
-4.75%
EBITDA MARGIN AVG TTM
-123.73%
EBITDA MARGIN AVG 3Y
-5.17%
EBITDA MARGIN AVG 5Y
-6.36%
EBITDA MARGIN AVG 10Y
-13.28%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+96.16%
CURRENT VS 3Y AVG
+8.19%
CURRENT VS 5Y AVG
+25.26%
CURRENT VS 10Y AVG
+64.23%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Tilray Brands, Inc.
Market Cap
$422.72M
EBITDA Margin
-4.75%
TTM Avg
-123.73%
3Y Avg
-5.17%
5Y Avg
-6.36%
Market Cap
$424.10M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$419.87M
EBITDA Margin
-1867.60%
TTM Avg
-990.65%
3Y Avg
-608.01%
5Y Avg
-2572.38%
Market Cap
$418.95M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$426.51M
EBITDA Margin
-211.30%
TTM Avg
-107.34%
3Y Avg
-56928.13%
5Y Avg
-38010.77%
Market Cap
$416.27M
EBITDA Margin
-189.54%
TTM Avg
-258.01%
3Y Avg
-315.18%
5Y Avg
-540.94%
Market Cap
$431.97M
EBITDA Margin
-14.39%
TTM Avg
-19.65%
3Y Avg
-40.36%
5Y Avg
-40.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | $422.72M | -4.75% | -123.73% | -5.17% | -6.36% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 0.24% | -1.36% | -6.49% | -5.53% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | -1867.60% | -990.65% | -608.01% | -2572.38% |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | -232.13% | -495.69% | -578.57% | -532.48% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -211.30% | -107.34% | -56928.13% | -38010.77% |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | -189.54% | -258.01% | -315.18% | -540.94% |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -14.39% | -19.65% | -40.36% | -40.72% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
Gross Margin
27.6%
EBITDA Margin
-4.8%
Operating Margin
-5.2%
Net Margin
-12.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-05-31 | 5.27% |
| 2026-02-28 | -1.51% |
| 2025-11-30 | -2.91% |
| 2025-08-31 | 8.43% |
| 2025-05-31 | -627.92% |
| 2025-02-28 | -390.99% |
| 2024-11-30 | -3.87% |
| 2024-08-31 | -2.38% |
| 2024-05-31 | 6.61% |
| 2024-02-29 | -26.15% |
| 2023-11-30 | -5.27% |
| 2023-08-31 | -2.02% |
| 2023-05-31 | -33.11% |
| 2023-02-28 | -805.67% |
| 2022-11-30 | -18.78% |
| 2022-08-31 | 8.41% |
| 2022-05-31 | -278.27% |
| 2022-02-28 | 12.47% |
| 2021-11-30 | -11.64% |
| 2021-08-31 | -17.88% |
| 2021-05-31 | -23.73% |
| 2021-02-28 | -12.00% |
| 2020-11-30 | -10.76% |
| 2020-08-31 | -49.24% |
| 2020-05-31 | -40.54% |
| 2020-03-31 | -3.04% |
| 2019-11-30 | 2.32% |
| 2019-09-30 | 10.48% |
| 2019-06-30 | -9.78% |
| 2019-03-31 | -91.74% |
| 2018-11-30 | -80.79% |
| 2018-09-30 | -171.37% |
| 2018-06-30 | -40.77% |
| 2018-02-28 | -66.39% |
| 2017-11-30 | -6.45% |
| 2017-09-30 | 32.84% |
| 2017-06-30 | 58.45% |
| 2017-02-28 | -80.41% |
| 2016-11-30 | 18.23% |
| 2016-08-31 | -176.90% |
| 2016-05-31 | 12.82% |
| 2016-02-29 | 5.84% |
| 2015-11-30 | -17.67% |
| 2015-08-31 | -44.15% |
| 2015-05-31 | -86.40% |
| 2015-02-28 | -644.68% |
